Definium Therapeutics Is Maintained at Outperform by Baird
Ratings actions from Benzinga: GMT) Definium Therapeutics Price Target Raised to $79.00/Share From $75.00 by BairdRatings actions from Benzinga
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.